Impact of adherence to statins on coronary artery disease in primary prevention
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
What is already known about this subject • There is a major gap between the use of statins in clinical trial settings and in actual practice. • Unfortunately, little is known about the impact of suboptimal use of statins on clinical outcomes. What this study adds • Patients who filled more than 90% of the prescribed doses began to achieve significant reductions in nonfatal coronary artery disease events. • Statin effectiveness is apparent after one full year of treatment. Aims: To evaluate the impact of adherence to statins on nonfatal coronary artery disease (CAD). Statins reduce cardiovascular morbidity and mortality after 1–2 years of continuous treatment. Studies have shown that <40% of patients take ≥80% of prescribed doses 1 year after starting therapy and that approximately half discontinue medication within 6 months of starting therapy. Methods: A cohort of 20 543 patients was reconstructed using the Régie de l'assurance maladie du Québec databases. Patients aged 50–64 years, without cardiovascular disease, and newly treated with statins between 1998 and 2000 were eligible. A nested case–control design was used to study nonfatal CAD. Every case was matched with 20 randomly selected controls. The adherence level was defined as the percentage of the prescribed medication doses used over a specified period and classified as ≥90% or <90%. Rate ratios (RR) of nonfatal CAD were determined through conditional logistic regression adjusted for age, sex, socioeconomic status, diabetes and hypertension. Results: The mean patient age was 58 years, 45% had hypertension and 19% had diabetes. Men represented 37% of the cohort. Among patients followed for >1 year, adherence of ≥90% was associated with fewer nonfatal CAD events (RR 0.81; 0.67, 0.97) compared with adherence <90%. In the multivariate model, male gender (RR 1.37; 1.16, 1.63), welfare recipients (RR 1.24; 1.04, 1.48), newly diagnosed hypertension (RR 3.54; 2.62, 4.77) and newly diagnosed diabetes mellitus (RR 1.97; 1.20, 3.24) were risk factors for CAD. Conclusion: The incidence of nonfatal CAD events decreases when >90% of the prescribed medications is used over at least 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Modeling and variable selection in epidemiologic analysis
Greenland, S. (1989) · American Journal of Public Health · doi:10.2105/ajph.79.3.340 · Cited by 2,208
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
Cited by
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis
Mann, D. M., Woodward, M., Muntner, P., Falzon, L., & Kronish, I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p150 · Cited by 329
Will Cardiovascular Disease Prevention Widen Health Inequalities?
Capewell, S., & Graham, H. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000320 · Cited by 328
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
De Vera, M. A., Bhole, V., Burns, L. C., & Lacaille, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12339 · Cited by 289
Bitton, A., Choudhry, N. K., Matlin, O. S., Swanton, K., & Shrank, W. H. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.09.004 · Cited by 256
Metadata
- Authors
- Bouchard, M., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-01-03
- Volume
- 63
- Issue
- 6
- Pages
- 698-708
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2026776049
- Cited by
- 99
- References
- 14
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of adherence to statins on coronary artery disease in primary prevention. https://app.cochat.ai/papers/10.1111/j.1365-2125.2006.02828.x
- The paper
- Bouchard, M., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S. (2007). Impact of adherence to statins on coronary artery disease in primary prevention. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2006.02828.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.